{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-ius-iud/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"5c7dee41-86ab-5d74-b647-984a7323f97c","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field b5f54bca-d20d-435a-9e23-3249920c9182 --><h2>Changes</h2><!-- end field b5f54bca-d20d-435a-9e23-3249920c9182 -->","summary":null,"htmlStringContent":"<!-- begin item 8b1926d6-a214-4a3f-bca2-df6fd67001ab --><!-- begin field 637db86d-da06-405b-9cd8-33965e7918fb --><p><strong>February 2021</strong> — reviewed. A literature search was conducted in January 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><ul><li>The topic structure has been changed.</li><li>Recommendations have been clarified in line with the updated Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Intrauterine contraception (April 2015, amended September 2019) </em>[FSRH, 2019].<span aria-describedby=\"cdk-describedby-message-49\"></span></li><li>The section on drug interaction of the levonorgestrel intrauterine system (LNG-IUS) with Esmya® (ulipristal acetate 5 mg) has been removed. This is because the licence for Esmya® has been suspended to protect public health while a safety review is conducted following cases of liver injury requiring transplant [MHRA, 2020].</li><li>The Quality and Outcomes Framework (QOF) indicators listed below have been removed as they were retired in April 2019 [BMS and NHS England, 2019]:<ul><li>CON001: The contractor establishes and maintains a register of women aged 54 or under who have been prescribed any method of contraception at least once in the last year, or other clinically appropriate interval, for example, the last 5 years for an IUS.</li><li>CON003: The percentage of women, on the register, prescribed emergency hormonal contraception one or more times in the preceding 12 months by the contractor who have received information from the contractor about long-acting reversible contraception at the time or within one month of the prescription.</li></ul></li></ul><!-- end field 637db86d-da06-405b-9cd8-33965e7918fb --><!-- end item 8b1926d6-a214-4a3f-bca2-df6fd67001ab -->","topic":{"id":"5fd4f695-2824-524f-97fd-1ffbc1ed1ad6","topicId":"14c8f64d-295a-4e1a-92b1-5280c3cce30f","topicName":"Contraception - IUS/IUD","slug":"contraception-ius-iud","lastRevised":"Last revised in February 2021","chapters":[{"id":"fa63ff86-38d1-5d04-b121-e6ba3a5b60d3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a6a86d04-8f24-5c92-b340-fe91a3323c4f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"841f70dc-d28e-5fb0-a68a-d6dac27e0ffb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5c7dee41-86ab-5d74-b647-984a7323f97c","slug":"changes","fullItemName":"Changes"},{"id":"24837e86-76a3-581e-ae6a-b827bf3bd948","slug":"update","fullItemName":"Update"}]},{"id":"abaf741b-ff01-59e1-8db9-510b749e87b7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b6f49269-86ef-5810-8059-10d065f377f0","slug":"goals","fullItemName":"Goals"},{"id":"a95a933e-1a31-5be4-9009-21b8a79da2ae","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"defba0ce-4495-5c71-8bfb-d04ee36d79e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f24f3c36-9720-5dd2-a7c5-8552fd694e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ff8474b0-1358-5b27-8928-58d81c1aeb7a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - options for local implementation"},{"id":"f10c46df-f19e-51c2-bd07-c680f266f212","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7a441ab2-b820-5821-8c27-5a2e71c741aa","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c7698130-9973-5145-aa0e-981a48972d36","slug":"definition","fullItemName":"Definition"},{"id":"9dbc8287-ded7-50ad-a43e-d87edeebb462","slug":"types","fullItemName":"Types"},{"id":"35c8bc48-3518-55a7-ae5a-a86db3ff3a56","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"aab10d36-adb8-52f6-895c-f7ce73e2ef4c","slug":"efficacy","fullItemName":"Efficacy"},{"id":"91843ac0-bc35-5798-b0e9-da4d52b30a69","slug":"advantages-disadvantages","fullItemName":"Advantages and disadvantages"},{"id":"6058a967-a6d7-52cd-9cf5-d2d480ec4d7d","slug":"where-to-obtain","fullItemName":"Where to obtain"}]},{"id":"98bf4d7c-c4c4-5c19-9821-a8c43bb9b0fe","fullItemName":"Management","slug":"management","subChapters":[{"id":"3aef47bd-6fd3-5fc1-a254-61098a484a64","slug":"levonorgestrel-intrauterine-system","fullItemName":"Scenario: Levonorgestrel intrauterine system"},{"id":"52ed621a-9a40-532d-ac51-ba401911db84","slug":"copper-intrauterine-device","fullItemName":"Scenario: Copper intrauterine device"}]},{"id":"08730ed3-ce27-5f45-b6fa-9747b4d35a64","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cfebd8c6-03b3-541a-8425-4f73a4eafe81","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"23a8e2fd-3eac-5088-919c-f81757e13399","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0f38e730-f213-59fe-afba-bf3f2f2b92e1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"64158eb2-3052-5f75-872c-1f839e443457","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a8fc3514-5b7d-55bb-a8d1-c58fb846dde6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71aff73b-554d-5df3-b36c-cc7490291d7f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fb77b532-9628-57cb-a96d-9533a61e730c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"841f70dc-d28e-5fb0-a68a-d6dac27e0ffb","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6a2842e1-157a-5ba6-b916-cecc1745cd49","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field efa96d2a-2fc3-4aae-85b5-0cf38f4b0bcb --><h3>Previous changes</h3><!-- end field efa96d2a-2fc3-4aae-85b5-0cf38f4b0bcb -->","summary":null,"htmlStringContent":"<!-- begin item 4f1c5230-a976-4035-82ee-6bc34babcad8 --><!-- begin field 68ab6150-e3b3-4c3f-8fb2-5f427eb91788 --><p><strong>July 2020 </strong>— minor update. Weight gain and decreased libido have been added as adverse effects of the levonorgestrel intrauterine device (LNG-IUS) in line with the updated manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>June 2020</strong> — minor update. Dizziness has been added as an adverse effect of the LNG-IUS in line with updated manufacturer's SPC.</p><p><strong>May 2019</strong> — minor update. Depression has been added as an adverse effect of the LNG-IUS in line with the manufacturer's SPC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-ius-iud/references/\">ABPI, 2019a</a>].</p><p><strong>March 2019</strong> — minor update. Kyleena® has been added as a type of LNG-IUS available in the UK, [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-ius-iud/references/\">ABPI, 2018</a>].</p><p><strong>January 2019 </strong>— minor update. Levosert® 20 micrograms/24 hours IDS is now licenced for up to 5 years use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-ius-iud/references/\">ABPI, 2019b</a>].</p><p><strong>February 2017</strong> — minor update. Recommendations on when to start a copper intrauterine device (Cu-IUD) or a LNG-IUS after pregnancy, miscarriage, or termination of pregnancy have been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Contraception after pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-ius-iud/references/\">FSRH, 2017</a>]. </p><p><strong>August to October 2016</strong> — reviewed. A literature search was conducted in June 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. Minor structural changes have been made.</p><p><strong>October 2015</strong> — minor update. The sections on Advantages, disadvantages, and risks have been updated to include additional information on uterine perforation as per the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Intrauterine contraception: uterine perforation.</em></p><p><strong>August 2013</strong> — minor update. Text added to clarify that when used for protection from endometrial hyperplasia during oestrogen replacement therapy, the LNG-IUS should be retained for no longer than 5 years after insertion (the licence states 4 years), regardless of the age of the woman at insertion.</p><p><strong>June 2013</strong> — minor update. The 2013 Quality and Outcomes Framework (QOF) options for local implementation have been added to this topic.</p><p><strong>March 2013</strong> — minor update. The telephone number for NHS Direct has been updated.</p><p><strong>January 2013</strong> — minor update. Change to the text to reflect updated advice from the FSRH regarding the interaction between Esmya® and hormonal contraceptives.</p><p><strong>February to June 2012</strong> — reviewed. A literature search was conducted in December 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made. However, recommendations have been rewritten for clarity, and superseded references and manufacturers' SPCs have been updated accordingly.</p><p><strong>January 2012</strong> — minor update. Typographical errors corrected. </p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>February 2010</strong> — updated to include the revised FSRH <em>UK Medical eligibility criteria for contraceptive use.</em></p><p><strong>March 2009</strong> — minor update. The QOF indicators for sexual health have been updated.</p><p><strong>September 2008</strong> — minor correction. Typographical and table heading corrections to UK medical eligibility criteria tables on CU-IUDs and LNG-IUSs.</p><p><strong>May 2008</strong> — update to text to reflect recommendations in the new FSRH guidance <em>Intrauterine contraception</em> 2007.</p><p><strong>April to September 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>January 2001</strong> — rewritten. Validated in March 2001 and issued in June 2001. Guidance on emergency contraception is no longer included but can be found as a separate CKS topic.</p><p><strong>December 1997</strong> — written.</p><!-- end field 68ab6150-e3b3-4c3f-8fb2-5f427eb91788 --><!-- end item 4f1c5230-a976-4035-82ee-6bc34babcad8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}